(Q26827426)

K. Tobinai

series ordinal

2

1 reference

T. Hotta

series ordinal

3

1 reference

M. Shimoyama

series ordinal

4

1 reference

language of work or name

1 reference

February 2012

1 reference

Japanese Journal of Clinical Oncology

published in

1 reference

volume

42

1 reference

issue

2

1 reference

page(s)

85-95

1 reference

Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109).

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Lymphoma Study Group (1984-1987)

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Pounding in the neck in supraventricular tachycardia

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Interferon alfa and zidovudine in adult T-cell leukemia-lymphoma. Lymphoma Study Group of the Japan Clinical Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Interferon alfa and zidovudine in adult T-cell leukemia-lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

1 reference

7 January 2021

Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Japan Clinical Oncology Group (JCOG)

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Alternating combination chemotherapy COP (cyclophosphamide, vincristine, prednisone) and MP (melphalan, prednisone) in multiple myeloma: a multicenter phase II study (JCOG8906). Lymphoma Study Group of the Japan Clinical Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Clinical trials for malignant lymphoma in Japan

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Development of Cancer Cooperative Groups in Japan

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Meta-Analysis on the Use of Zidovudine and Interferon-Alfa in Adult T-Cell Leukemia/Lymphoma Showing Improved Survival in the Leukemic Subtypes

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Multiple myeloma and amyloidosis: an evolving treatment paradigm toward the goal of tailored therapy

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Advanced insights into the biology of malignant lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

A phase II study of VEPA/FEPP chemotherapy for aggressive lymphoma in elderly patients: Japan Clinical Oncology Group Study JCOG9203.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

The future of CD20 monoclonal antibody therapy in B-cell malignancies

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021

Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYR168

7 January 2021